Fee and Kasarskis12 described a 66-yearold- diabetic man who developed facial weakness and bulbar signs after 6 years of etanercept therapy for rheumatoid arthritis. The patient had an elevated titer of acetylcholine receptor antibodies (AChR-Ab), and electrophysiologic studies suggested a disorder of neuromuscular transmission associated with axonal polyneuropathy. No immunomodulating therapy was given. After 3–8 months off etanercept his clinical and electrophysiologic features improved, but AChR-Ab titer remained elevated. We recently encountered a 68-year-old woman who experienced fluctuating fatigability 7–8 months after starting etanercept (Enbrel; Wyeth Lederle SpA) taken weekly (50 mg autoinjected subcutaneously) to treat psoriatic arthritis.
Comment on myasthenia gravis associated with TNF-alpha receptor blockers: A multifaceted issue / G., Galassi; A., Ariatti; L., Codeluppi; Meletti, Stefano. - In: MUSCLE & NERVE. - ISSN 0148-639X. - 42:2(2010), pp. 296-298. [10.1002/mus.21748]
Comment on myasthenia gravis associated with TNF-alpha receptor blockers: A multifaceted issue
MELETTI, Stefano
2010-01-01
Abstract
Fee and Kasarskis12 described a 66-yearold- diabetic man who developed facial weakness and bulbar signs after 6 years of etanercept therapy for rheumatoid arthritis. The patient had an elevated titer of acetylcholine receptor antibodies (AChR-Ab), and electrophysiologic studies suggested a disorder of neuromuscular transmission associated with axonal polyneuropathy. No immunomodulating therapy was given. After 3–8 months off etanercept his clinical and electrophysiologic features improved, but AChR-Ab titer remained elevated. We recently encountered a 68-year-old woman who experienced fluctuating fatigability 7–8 months after starting etanercept (Enbrel; Wyeth Lederle SpA) taken weekly (50 mg autoinjected subcutaneously) to treat psoriatic arthritis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
